Unique site-specific dual-payload glycan conjugation platform
About antibody-drug conjugates (ADC)
Antibody-drug conjugates (ADCs) are a class of therapeutics, in which the drugs can be attached to the antibody through specific linkers and conjugation methods.
References
- Carter PJ et al. Cancer J. 2008;14(3):154-169.
- Senter PD. Curr Opin Chem Biol. 2009;13(3):235-244. 3. Polson AG et al. Cancer Res. 2009;69(6):2358
Unique Conjugation Technology
HoneyBear Biosciences' proprietary conjugation belongs to the new generation of site-specific conjugation technology. The core technology utilizes glycan conjugation.
| Specificity | Advantage |
|---|---|
| Precisely Conjugation site and conjugation ratio | Efficacy, stability and safety increase |
| No antibody sequence mutation is needed | Time and cost effective |
| Can Conjugate Two different payloads | Wider application, efficacy and response rate increase, resistance decrease |
| ADC products are more homogeneous | Efficacy, stability and safety increase |
| Exhibit high yield conjugation with easily purified | Time and cost effective |
Facile dual-payload synthesis
Combination of Different MOA Payloads
Enhance Efficacy; Decrease Resistance; Stimulate Immune Response
Different MOA Payloads
- Tubulin inhibitor; DNA binder; Topo-I inhibitor
- Different Agents
- Radioisotope; protein degrader; immune modulator
Leveraging on HoneyBear’s Technologies to Revolutionize Next Generation ADC
1. Facile dual payload synthesis sets high barriers to entry
2. Dual payload concepts address multiple medical challenges that single payload ADCs current face
- Low response rate
- Short duration of response
- Resistance
3. Dual payload technologies enable attacking tumor at multiple fronts
- Different yet complementary Mechanism of Action
- Additive or synergistic effects
- Induce endogenous anti-cancer immune response to achieve long term remission
4. First-in-class and Best-in-class warrant enormous market potentials
Unique site-specific dual-payload glycan conjugation platform
HoneyBear’s patented unique site-specific dual-payload glycan conjugation platform
US11085062B2
JP06888764B2
CA3048452C
AU201717388556B2
TWI673363B
KR2294517B1
Patent : Process For Preparing Glycoprotein-Drug Conjugates
- Anticipated expiration: 2037-12-29
- Priority Date: US Provisional 62/440075, 29 Dec. 2016
- WO2018126092A1, EP3568161A4, CN110121365A (OA)
